We teach your immune system to attack and cure cancer
Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2023
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
